China Shineway Pharmaceutical Group Limited (CSWYF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China Shineway Pharmaceutical Group Limited (CSWYF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 51/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026China Shineway Pharmaceutical Group Limited (CSWYF) Gesundheitswesen & Pipeline-Uebersicht
China Shineway Pharmaceutical Group Limited researches, develops, manufactures, and trades Chinese medicines, including modern formulations and TCM granules, targeting diverse therapeutic areas like cardio-cerebrovascular and pediatrics. Operating primarily in China and Hong Kong, the company distinguishes itself through a focus on traditional Chinese medicine within the broader healthcare sector.
Investmentthese
China Shineway Pharmaceutical Group Limited presents a compelling investment case based on its established presence in the Chinese medicine market and its diversified product portfolio. With a P/E ratio of 7.38 and a profit margin of 24.8%, the company demonstrates strong profitability and efficient operations. The dividend yield of 5.52% offers an attractive income stream for investors. Key growth catalysts include increasing demand for traditional Chinese medicine and the company's expansion into new therapeutic areas. However, potential risks include regulatory changes in the pharmaceutical industry and competition from other drug manufacturers. The company's beta of 0.87 suggests lower volatility compared to the broader market. Investors may want to evaluate the company's financial stability, growth prospects, and risk factors before making an investment decision.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.76B indicates a substantial presence in the pharmaceutical market.
- P/E Ratio of 7.38 suggests the company may be undervalued compared to its earnings.
- Profit Margin of 24.8% demonstrates efficient operations and strong profitability.
- Gross Margin of 73.4% reflects the company's ability to manage production costs effectively.
- Dividend Yield of 5.52% provides an attractive income stream for investors.
Wettbewerber & Vergleichsunternehmen
Staerken
- Established presence in the Chinese medicine market.
- Diversified product portfolio across multiple therapeutic areas.
- Strong gross margin of 73.4%.
- High profit margin of 24.8%.
Schwaechen
- Reliance on the Chinese market.
- Potential impact from regulatory changes in the pharmaceutical industry.
- Limited geographic diversification.
- Dependence on traditional Chinese medicine, which may face evolving consumer preferences.
Katalysatoren
- Ongoing: Increasing demand for traditional Chinese medicine in both domestic and international markets.
- Ongoing: Expansion of the company's product portfolio into new therapeutic areas.
- Upcoming: Potential regulatory approvals for new drug formulations.
- Ongoing: Strategic partnerships and collaborations with other pharmaceutical companies.
- Ongoing: Government support for the development of the pharmaceutical industry in China.
Risiken
- Potential: Regulatory changes in the pharmaceutical industry could impact the company's operations.
- Potential: Competition from other pharmaceutical companies may erode market share.
- Potential: Pricing pressures and reimbursement challenges could reduce profitability.
- Potential: Adverse events or product recalls could damage the company's reputation.
- Ongoing: Dependence on the Chinese market exposes the company to economic and political risks.
Wachstumschancen
- Expansion into New Therapeutic Areas: China Shineway Pharmaceutical can capitalize on the growing demand for specialized medicines by expanding its product offerings into new therapeutic areas such as oncology and immunology. These areas represent significant market opportunities with increasing prevalence of related diseases. Investing in research and development to create innovative TCM-based treatments for these conditions could drive substantial revenue growth. The global oncology market is projected to reach $286 billion by 2030, presenting a lucrative target for expansion.
- Increased Investment in Research and Development: A greater focus on R&D will allow China Shineway Pharmaceutical to develop novel drug formulations and improve existing products. This can lead to increased market share and higher profit margins. Government support for pharmaceutical innovation in China provides a favorable environment for R&D investments. By allocating more resources to research, the company can create a pipeline of new products that address unmet medical needs and drive long-term growth.
- Geographic Expansion within China: Expanding its distribution network to cover more regions within China can significantly increase China Shineway Pharmaceutical's market reach. Focusing on Tier 2 and Tier 3 cities, where healthcare access is still developing, presents a significant opportunity. Establishing partnerships with local hospitals and pharmacies can facilitate market entry and build brand recognition. The Chinese pharmaceutical market is highly fragmented, offering ample opportunities for expansion.
- Leveraging E-commerce Platforms: Utilizing e-commerce platforms to sell its products directly to consumers can enhance China Shineway Pharmaceutical's sales and marketing efforts. Online channels provide a cost-effective way to reach a wider audience and improve customer engagement. Investing in digital marketing and building a strong online presence can drive significant revenue growth. The e-commerce market in China is one of the largest in the world, offering a vast potential customer base.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies or acquiring smaller players can accelerate China Shineway Pharmaceutical's growth. Collaborations can provide access to new technologies, markets, and distribution channels. Acquisitions can expand the company's product portfolio and increase its market share. Identifying synergistic opportunities and executing strategic deals can create significant value for shareholders.
Chancen
- Expansion into new therapeutic areas such as oncology and immunology.
- Increased investment in research and development to create innovative products.
- Geographic expansion within China, focusing on Tier 2 and Tier 3 cities.
- Leveraging e-commerce platforms to reach a wider audience.
Risiken
- Competition from other pharmaceutical companies.
- Pricing pressures and reimbursement challenges.
- Changes in government regulations and policies.
- Potential for adverse events or product recalls.
Wettbewerbsvorteile
- Established Brand: China Shineway Pharmaceutical has built a recognized brand in the Chinese medicine market.
- Product Diversification: The company offers a wide range of products across various therapeutic areas.
- Distribution Network: The company has an established distribution network in China and Hong Kong.
- Research and Development Capabilities: The company invests in R&D to develop new and innovative products.
Ueber CSWYF
China Shineway Pharmaceutical Group Limited, established in 2004 and headquartered in Shijiazhuang, China, is an investment holding company specializing in the research, development, manufacture, and trade of Chinese medicines. As a subsidiary of Forway Investment Limited, the company plays a significant role in the production and distribution of both modern and traditional Chinese medicine formulations. Its product portfolio includes soft capsules, granules, and injections of modern Chinese medicines, as well as TCM (Traditional Chinese Medicine) Formula Granules. These products cater to a wide range of therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. Shineway Pharmaceutical's commitment to both modern and traditional approaches allows it to address a broad spectrum of healthcare needs within its primary markets of China and Hong Kong. The company also engages in the trade of agricultural products, diversifying its business interests. Through continuous research and development, China Shineway Pharmaceutical aims to innovate and improve its product offerings, maintaining a competitive edge in the dynamic pharmaceutical market. The company's integrated approach, from research to distribution, enables it to maintain quality control and ensure the efficacy of its medicines.
Was das Unternehmen tut
- Researches and develops Chinese medicines.
- Manufactures modern Chinese medicines in various forms (soft capsules, granules, injections).
- Produces TCM (Traditional Chinese Medicine) Formula Granules.
- Trades Chinese medicines in the People's Republic of China and Hong Kong.
- Offers products for cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology therapeutic areas.
- Trades in agricultural products.
Geschaeftsmodell
- Develops and manufactures a range of Chinese medicines, both modern and traditional.
- Sells its products through distributors and directly to hospitals and pharmacies.
- Generates revenue from the sale of pharmaceutical products and agricultural products.
Branchenkontext
China Shineway Pharmaceutical Group Limited operates within the specialty and generic drug manufacturing industry, a segment experiencing growth driven by increasing healthcare expenditure and demand for affordable medicines. The Chinese pharmaceutical market is characterized by a blend of traditional Chinese medicine and modern pharmaceuticals. Key competitors include AIHLF, CCHWF, EBRCZ, IVEVF, and KDGTF. The industry faces regulatory scrutiny and pricing pressures, but also benefits from government support for local pharmaceutical companies. China's aging population and rising chronic disease rates are expected to further fuel demand for pharmaceutical products.
Wichtige Kunden
- Hospitals and clinics in China and Hong Kong.
- Pharmacies and drug stores.
- Patients seeking Chinese medicine treatments.
- Distributors of pharmaceutical products.
Finanzdaten
Chart & Info
China Shineway Pharmaceutical Group Limited (CSWYF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CSWYF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CSWYF.
Kursziele
Wall-Street-Kurszielanalyse fuer CSWYF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CSWYF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Zhenjiang Li
CEO
Zhenjiang Li is the CEO of China Shineway Pharmaceutical Group Limited, leading a workforce of 3220 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on traditional Chinese medicine. He has a strong understanding of the Chinese healthcare market and regulatory environment. Prior to his role at China Shineway Pharmaceutical, he held various leadership positions in pharmaceutical manufacturing and distribution companies.
Erfolgsbilanz: Under Zhenjiang Li's leadership, China Shineway Pharmaceutical has maintained a strong market position and achieved consistent profitability. He has overseen the expansion of the company's product portfolio and the strengthening of its distribution network. His strategic decisions have contributed to the company's growth and success in the competitive pharmaceutical market.
CSWYF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Shineway Pharmaceutical Group Limited may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting or may not be current in their disclosures. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of stringent listing standards and regulatory oversight.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure may hinder comprehensive analysis.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- OTC Other tier companies face less regulatory oversight, increasing the risk of fraud or mismanagement.
- The company's financial health and operations may not be as transparent as those of exchange-listed companies.
- Potential for delisting or suspension of trading due to non-compliance with OTC market regulations.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Analyze the company's business model and competitive landscape.
- Evaluate the company's compliance with relevant regulations.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- The company has been in operation since 2004.
- It has a substantial number of employees (3220).
- The company has a positive profit margin of 24.8%.
- The company has a dividend yield of 5.52%.
- The company's products are used in various therapeutic areas.
Haeufige Fragen zu CSWYF
What are the key factors to evaluate for CSWYF?
China Shineway Pharmaceutical Group Limited (CSWYF) currently holds an AI score of 51/100, indicating moderate score. Key strength: Established presence in the Chinese medicine market.. Primary risk to monitor: Potential: Regulatory changes in the pharmaceutical industry could impact the company's operations.. This is not financial advice.
How frequently does CSWYF data refresh on this page?
CSWYF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CSWYF's recent stock price performance?
Recent price movement in China Shineway Pharmaceutical Group Limited (CSWYF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established presence in the Chinese medicine market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CSWYF overvalued or undervalued right now?
Determining whether China Shineway Pharmaceutical Group Limited (CSWYF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CSWYF?
Before investing in China Shineway Pharmaceutical Group Limited (CSWYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CSWYF to a portfolio?
Potential reasons to consider China Shineway Pharmaceutical Group Limited (CSWYF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Established presence in the Chinese medicine market.. Additionally: Diversified product portfolio across multiple therapeutic areas.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CSWYF?
Yes, most major brokerages offer fractional shares of China Shineway Pharmaceutical Group Limited (CSWYF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CSWYF's earnings and financial reports?
China Shineway Pharmaceutical Group Limited (CSWYF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CSWYF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- OTC data may be less reliable than exchange-listed data.
- Analyst coverage may be limited due to OTC listing.